Reading TSHA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TSHA free→Reading TSHA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TSHA free→QuarterlyIQ Insights · TSHA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. As previously disclosed, Taysha Gene Therapies, Inc. (the “ Company ”) is party to that certain Sales Agreement, dated October 5, 2021, as amended by that certain Amendment No. 1, dated March 30, 2022 (as so amended, the “ Sales Agreement ”), with Goldman Sachs & Co. LLC, Wells Fargo Securities, LLC and Leerink Partners LLC, as sales agents (the “ Sales Agents ”). Under the Sales Agreement, the Company may offer and sell, from time to time, through…
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events. Launch and Pricing of the Offering On May 28, 2025, the Company issued a press release announcing that it had commenced the Offering. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In connection with the Offering, the Company filed a preliminary prospectus supplement to the Registration Statement. The preliminary prospectus supplement described certain elements of the Company’s business s…
Entry into a Material Definitive Agreement. On May 28, 2025, Taysha Gene Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC, BofA Securities, Inc., Piper Sandler & Co. and Barclays Capital Inc., as representatives of the several underwriters set forth therein (collectively, the “ Underwriters ”), to issue and sell 46,868,687 shares of common stock of the Company, par value $0.00001 per share (“ Common Stock ”), and, in…
Other Events. Clinical and Regulatory Update Presentation On May 28, 2025, the Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. ATM Prospectus On May 28 , 2025, the Company notified the Agents (as defined below) that it was suspending and terminating the prospectus (the “ ATM Prospectus ”) related to up to $100,000,000 of the Company’s com…
Other Events. Clinical and Regulatory Update Presentation On May 28, 2025, the Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. ATM Prospectus On May 28 , 2025, the Company notified the Agents (as defined below) that it was suspending and terminating the prospectus (the “ ATM Prospectus ”) related to up to $100,000,000 of the Company’s com…
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.